<SEC-DOCUMENT>0001193125-19-138982.txt : 20190507
<SEC-HEADER>0001193125-19-138982.hdr.sgml : 20190507
<ACCEPTANCE-DATETIME>20190507083153
ACCESSION NUMBER:		0001193125-19-138982
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20190507
DATE AS OF CHANGE:		20190507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANNKIND CORP
		CENTRAL INDEX KEY:			0000899460
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133607736
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-230633
		FILM NUMBER:		19801374

	BUSINESS ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 300
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
		BUSINESS PHONE:		818-661-5000

	MAIL ADDRESS:	
		STREET 1:		30930 RUSSELL RANCH ROAD
		STREET 2:		SUITE 300
		CITY:			WESTLAKE VILLAGE
		STATE:			CA
		ZIP:			91362
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d742534d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-230633 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
April&nbsp;5, 2019) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g742534g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a
Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement, or sales agreement, with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.01 par value per share,
offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, from time to time we may offer and sell shares of our common stock having an aggregate gross sales price of up to
$50.0&nbsp;million through Cantor Fitzgerald, acting as sales agent, pursuant to this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common
stock is listed on The Nasdaq Global Market under the symbol &#147;MNKD.&#148; On May&nbsp;1, 2019, the last reported sale price of our common stock as reported on The Nasdaq Global Market was $1.47 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement may be made in sales deemed to be an &#147;at the market offering&#148; as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to terms of the sales agreement, Cantor Fitzgerald is not required to sell any specific number or dollar amount of securities but will act as our
sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or similar
arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will be entitled to a commission of up to 3.0% of the gross sales price of any shares sold under the sales agreement. In
connection with the sale of our common stock on our behalf, Cantor Fitzgerald will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting
commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#suprom742534_3">Risk
 Factors</A>&#148; on <FONT STYLE="white-space:nowrap">page&nbsp;S-5</FONT> of this prospectus supplement, and under similar headings in the documents that are incorporated by reference into this prospectus supplement and the accompanying
prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g742534g55u86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is May&nbsp;7, 2019 </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_7">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_10">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom742534_11">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to an offering of our common stock. Before buying any of the common stock that we are
offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference as described under the headings &#147;Where You Can Find More Information&#148; and
&#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement. These documents contain important information that you should consider when making your investment decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, references in this prospectus supplement and the accompanying prospectus to &#147;MannKind,&#148; the
&#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MannKind Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is
this prospectus supplement, which describes the terms of this offering of common stock and also adds to, updates and changes information contained in the accompanying prospectus and the documents incorporated by reference. The second part is the
accompanying prospectus, which gives more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent the information contained in this prospectus supplement differs from
or conflicts with the information contained in the accompanying prospectus or any document incorporated by reference, the information in this prospectus supplement will control. If any statement in one of these documents is inconsistent with a
statement in another document having a later date&#151;for example, a document incorporated by reference into this prospectus supplement and the accompanying prospectus&#151;the statement in the document having the later date modifies or supersedes
the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the sales agent has not, authorized anyone to provide you with information different from that which is contained
in or incorporated by reference in this prospectus supplement, the accompanying prospectus and in any free writing prospectus that we may authorize for use in connection with this offering. No one is making offers to sell or seeking offers to buy
these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only and that
any information we have incorporated by reference or included in the accompanying prospectus is accurate only as of the date given in the document incorporated by reference or as of the date of the prospectus, as applicable, regardless of the time
of delivery of this prospectus supplement, the accompanying prospectus, any related free writing prospectus, or any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since those dates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is
incorporated by reference into this prospectus supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such
agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and
covenants should not be relied on as accurately representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus
and the information incorporated herein and therein by reference include trademarks, servicemarks and tradenames owned by us or other companies. Afrezza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Technosphere<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are our trademarks in the United States. We have also applied for other trademark registrations and have registered company trademarks in other jurisdictions. All trademarks, servicemarks and
tradenames included or incorporated by reference in this prospectus supplement or the accompanying prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us and this offering and selected information contained elsewhere in or incorporated by reference into
this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of
our company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference into this prospectus
supplement and the accompanying prospectus, and the information included in any free writing prospectus that we authorize for use in connection with this offering, including the information contained in and incorporated by reference under the
heading &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-5</FONT> of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into
this prospectus supplement and the accompanying prospectus. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes
and pulmonary arterial hypertension. Our only approved product, Afrezza, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration in June 2014 to improve glycemic control in adult patients with diabetes. Afrezza
became available by prescription in United States retail pharmacies in February 2015. According to the Centers for Disease Control and Prevention, 30.3&nbsp;million people in the United States had diabetes in 2015. Globally, the International
Diabetes Federation has estimated that approximately 425.0&nbsp;million people had diabetes in 2017 and approximately 629.0&nbsp;million people will have diabetes by 2045. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, we promote Afrezza to endocrinologists and certain high-prescribing primary care physicians through our specialty sales force.&nbsp;To support our
sales efforts, we have implemented several patient and physician support programs, including a <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance and product savings program, direct purchase and our MannKind Cares program that supports
providers and patients who have questions about insurance coverage, prescription cost and product use. We have also entered into a number of rebate or other agreements with various payors and pharmacy benefit managers that are intended to facilitate
more favorable insurance coverage for Afrezza. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, we may seek to supplement our sales force through a
<FONT STYLE="white-space:nowrap">co-promotion</FONT> arrangement with a third party that has an underutilized primary care sales force, that can be used to promote Afrezza to greater number of primary care physicians in the United States.
Internationally, our strategy is to establish regional partnerships in foreign jurisdictions where there are commercial opportunities, subject to receipt of the necessary foreign regulatory approvals. In May 2017 we entered into a supply and
distribution agreement with Biomm S.A. to pursue regulatory approval and commercialization of Afrezza in Brazil. In May 2018, we entered into a similar agreement with Cipla Ltd. for the regulatory approval and commercialization of Afrezza in India.
Our partners have not yet commenced commercialization in their respective territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe there are additional opportunities for our proprietary
Technosphere and inhaler technologies for the delivery of active pharmaceutical ingredients (&#147;API&#148;). We believe that our proprietary Technosphere formulation technology represents a versatile drug delivery platform that may allow the oral
inhalation of a wide range of API. We have successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules. Technosphere powders are based on our proprietary
excipient, fumaryl diketopiperazine, which is a <FONT STYLE="white-space:nowrap">pH-sensitive</FONT> organic molecule that self-assembles into small particles under acidic conditions. Certain drugs, such as insulin and treprostinil, can be loaded
onto these particles by combining a solution of the drug with a solution or suspension of Technosphere material, which is then dried to powder form. The resulting powder has a consistent and narrow range of particle sizes with good aerodynamic
properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve quickly </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when the particles contact the moist lung surface with its neutral pH, releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to
provide excellent systemic exposure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also created an innovative line of breath-powered, dry powder inhalers. Our inhalers are easy to use,
cost-effective and can be produced in both a reusable (chronic treatment) and a <FONT STYLE="white-space:nowrap">single-use</FONT> (acute treatment) format. Both the reusable and single use inhaler formats use the same internal <FONT
STYLE="white-space:nowrap">air-flow</FONT> design. Being breath-powered, our inhalers require only the patient&#146;s inhalation effort to deliver the powder. To administer the inhalation powder, a patient loads a cartridge into our inhaler and
inhales through the mouthpiece. Upon inhalation, the dry powder is lifted out of the cartridge and broken (or <FONT STYLE="white-space:nowrap">de-agglomerated)</FONT> into small particles. The inhalers are engineered to produce an aggressive
airstream to <FONT STYLE="white-space:nowrap">de-agglomerate</FONT> the powder while keeping the powder moving slowly. This slow-moving powder effectively navigates the patient&#146;s airways for delivery into the lung with minimal deposition at the
back of the throat. Our inhalers show very little change in performance (i.e., efficient cartridge emptying) over a wide range of inhalation efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in the State
of Delaware on February&nbsp;14, 1991. Our principal executive offices are located at 30930 Russell Ranch Road, Suite 300, Westlake Village, California 91362, and our telephone number at that address is (818)
<FONT STYLE="white-space:nowrap">661-5000.</FONT> MannKind Corporation and the MannKind Corporation logo are our service marks. Our website address is http://www.mannkindcorp.com. The information contained in, and that can be accessed through, our
website is not incorporated into and does not form a part of this prospectus supplement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $50,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of offering </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time through our sales agent, Cantor Fitzgerald. See &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-10</FONT> of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses, general and administrative expenses,
and other expenses associated with the commercialization of Afrezza, any other product candidate we develop and our Technosphere drug delivery platform. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this
prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See the information contained in or incorporated by reference under the heading &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-5</FONT> of this prospectus
supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and any free writing prospectus that we authorize for use in connection with this offering. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market symbol </P></TD>
<TD>&#147;MNKD&#148; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our securities involves a high degree of risk. You should carefully consider the risks described below and discussed under the section
captioned &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018, as updated by our annual, quarterly and other reports and documents that are
incorporated by reference into this prospectus supplement, and all other information contained in this prospectus supplement and the accompanying prospectus and incorporated by reference in this prospectus supplement and the accompanying prospectus,
and in any free writing prospectus that we have authorized for use in connection with this offering, before purchasing shares of our common stock. These risks and uncertainties are not the only ones facing us. Additional risks and uncertainties that
we are unaware of, or that we currently deem immaterial, also may become important factors that affect us. If any of such risks or the risks described below or in our SEC filings occur, our business, financial condition or results of operations
could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose some or all of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will
have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have not
designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those
contemplated at the time of this offering. Our management may use the net proceeds for purposes that may not improve our financial condition or market value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior to this offering. Assuming
that an aggregate of 34,013,605 shares of our common stock are sold at an assumed offering price of $1.47 per share pursuant to this prospectus supplement, which was the last reported sale price of our common stock on the Nasdaq Global Market on
May&nbsp;1, 2019, for aggregate gross proceeds of $50.0&nbsp;million, after deducting commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $2.10 per share, representing the difference
between our as adjusted net tangible book deficit per share as of March&nbsp;31, 2019 after giving effect to this offering at the assumed offering price. The exercise of outstanding stock options and warrants or settlement of outstanding restricted
stock units may result in further dilution of your investment. See &#147;Dilution&#148; in this prospectus supplement for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for
our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable
into common stock, in future transactions may be higher or lower than the price per share paid by any investors in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein, contain statements
that are not strictly historical in nature and are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act. These forward-looking statements are subject to the &#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully market, commercialize and achieve market acceptance for Afrezza or any other product
candidates or therapies that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manufacture sufficient quantities of Afrezza and obtain insulin supply as needed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our Technosphere drug delivery platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates for future performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding anticipated operating losses and financial results and our needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress or success of our research, development and clinical programs, including the application for and
receipt of regulatory clearances and approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property and operate our business without infringing upon the
intellectual property rights of others; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scientific studies and the conclusions we draw from them; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the
negative of these words and words or similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and
subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ materially from
those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#147;Risk Factors&#148; in this prospectus supplement, in the accompanying prospectus, and in our filings
with the Securities and Exchange Commission, or SEC. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by
these cautionary statements. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time
means that actual events are bearing out as expressed or implied in such forward-looking statements. Before deciding to purchase shares of our common stock, you should carefully consider the risk factors discussed or incorporated by reference
herein, in addition to the other information set forth in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50.0&nbsp;million from time to time. Because there is no minimum
offering amount required in this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. There can be no assurance that we will sell any shares under or fully utilize the sales
agreement with Cantor Fitzgerald as a source of financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering for general corporate purposes, including
manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses, general and administrative expenses, and other expenses associated with the commercialization of Afrezza, any other product candidate
we develop and our Technosphere drug delivery platform. We may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies. Although we have no specific agreements, commitments or understandings
with respect to any acquisition, we evaluate acquisition opportunities and engage in related discussions with other companies from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
the date of this prospectus supplement, we cannot specify with certainty all of the particular uses of the proceeds, if any, from this offering. Accordingly, we will retain broad discretion over the use of any such proceeds. Pending the use of the
net proceeds, from this offering as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public
offering price per share and the as adjusted net tangible book deficit per share of our common stock after this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book deficit
as of March&nbsp;31, 2019 was approximately $(188.0) million, or $(1.00) per share. We calculate net tangible book value (deficit) per share by dividing the net tangible book value (deficit), which is tangible assets less total liabilities, by the
number of outstanding shares of our common stock. Dilution represents the difference between the portion of the amount per share paid by purchasers of shares in this offering and the as adjusted net tangible book deficit per share of our common
stock immediately after giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the assumed sale by us of shares of our common stock in the aggregate
amount of $50.0&nbsp;million in this offering at an assumed offering price of $1.47 per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on May&nbsp;1, 2019, and after deducting commissions and estimated
aggregate offering expenses payable by us, our as adjusted net tangible book deficit as of March&nbsp;31, 2019 would have been approximately $(139.6)&nbsp;million, or $(0.63) per share of common stock. This represents an immediate increase in net
tangible book value per share of $0.37 to our existing stockholders and an immediate dilution in net tangible book value per share of $2.10 to new investors purchasing common stock in this offering. The following table illustrates this dilution on a
per share basis to new investors participating in this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book deficit per share as of March&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book deficit per share after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above assumes, for illustrative purposes, that an aggregate of shares of our common stock are sold at a price of
$1.47 per share, the last reported sale price of our common stock on the Nasdaq Global Market on May&nbsp;1, 2019, for aggregate gross proceeds of $50.0&nbsp;million. The shares sold in this offering, if any, will be sold from time to time at
various prices. An increase of $0.50 per share in the price at which the shares are sold from the assumed offering price of $1.47 per share shown in the table above, assuming all of our common stock in the aggregate amount of $50.0&nbsp;million
under the sales agreement with Cantor Fitzgerald is sold at that price, would result in an increase in the dilution in net tangible book value per share to new investors in this offering to $2.53 per share, after deducting commissions and estimated
aggregate offering expenses payable by us. A decrease of $0.50 per share in the price at which the shares are sold from the assumed offering price of $1.47 per share shown in the table above, assuming all of our common stock in the aggregate amount
of $50.0&nbsp;million under the sales agreement with Cantor Fitzgerald is sold at that price, would result in a decrease in the dilution in net tangible book value per share to new investors in this offering to $1.67 per share, after deducting
commissions and estimated aggregate offering expenses payable by us. This information is supplied for illustrative purposes only and may differ based on the actual offering price and the actual number of shares offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above discussion and table are based on 187,778,236 shares of our common stock outstanding as of March&nbsp;31, 2019 and exclude, as of that date: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">10,846,738 shares of common stock issuable upon the exercise of outstanding stock options with a weighted average
exercise price of $5.40 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,314,218 shares of common stock issuable upon the settlement of outstanding restricted stock units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">8,663,530 shares of common stock available for future grant under our 2018 equity incentive plan;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">2,601,341 shares of common stock issuable under our employee stock purchase plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">31,851 shares of common stock issuable upon the exercise of outstanding warrants at an exercise price of $13.05
per share, which warrants expire on November&nbsp;16, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">26,666,667 shares of common stock issuable upon the exercise of outstanding warrants at an exercise price of
$1.60 per share, which warrants expire on December&nbsp;26, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,629,127 shares of common stock issuable upon the conversion of our 5.75% senior convertible notes due 2021 at a
conversion price of approximately $5.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">21,909,541 shares of common stock issuable upon conversion of our promissory note with The Mann Group LLC
(principal plus accrued and unpaid interest thereon as of March&nbsp;31, 2019) at a conversion price of $4.00 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">14,000,000 shares of common stock issuable upon the exercise of outstanding warrants at an exercise price of
$2.38 per share, which warrants expired on April&nbsp;9, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that outstanding options or warrants are exercised or
outstanding restricted units are settled, investors purchasing shares in this offering could experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe
we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or equity-based securities, the issuance of these securities could result in further dilution to our
stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_7"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales Agreement with Cantor Fitzgerald, under which
from time to time we may issue and sell shares of our common stock having an aggregate gross sales price of up to $50.0&nbsp;million through Cantor Fitzgerald acting as agent. Sales of the shares of common stock, if any, may be made on The Nasdaq
Global Market at market prices and such other sales as agreed upon by us and Cantor Fitzgerald. We will file the sales agreement as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> which is incorporated by
reference in this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cantor
Fitzgerald may offer and sell shares of our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct Cantor Fitzgerald not to
sell common stock if the sales cannot be effected at or above the price designated by us from time to time. We or Cantor Fitzgerald may suspend or terminate the offering of our common stock upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay Cantor Fitzgerald commissions, in cash, for its services in acting as sales agent in the sale of our common stock. Cantor Fitzgerald will be
entitled to a commission of up to 3.0% of the gross sales price per share sold under the sales agreement. Because there is no minimum offering amount required as a condition to this offering, the actual total public offering amount, commissions and
proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse a portion of Cantor Fitzgerald&#146;s expenses, including legal fees, in connection with this offering up to a maximum of $50,000. We estimate that the total
expenses for the offering, excluding commissions and expense reimbursement payable to Cantor Fitzgerald under the terms of the sales agreement, will be approximately $100,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Settlement for sales of shares of our common stock will occur on the second trading day following the date on which any sales are made (or such earlier day as
is industry practice for <FONT STYLE="white-space:nowrap">regular-way</FONT> trading), or on some other date that is agreed upon by us and Cantor Fitzgerald in connection with a particular transaction, in return for payment of the net proceeds to
us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by
such other means as we and Cantor Fitzgerald may agree upon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald will act as our sales agent and use commercially reasonable efforts,
consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of The Nasdaq Global Market. In connection with the sale of the common stock on our behalf, Cantor Fitzgerald will be
deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to
Cantor Fitzgerald against certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offering of shares of our common stock pursuant
to the sales agreement will terminate upon the earlier of (1)&nbsp;the sale of all shares of our common stock subject to the sales agreement, or (2)&nbsp;termination of the sales agreement as permitted therein. We and Cantor Fitzgerald may each
terminate the sales agreement at any time upon ten days&#146; prior notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald and its affiliates may in the future provide various
investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, Cantor Fitzgerald will not engage in any market
making activities involving our common stock while the offering is ongoing under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the
accompanying prospectus in electronic format may be made available on a website maintained by Cantor Fitzgerald and Cantor Fitzgerald may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the issuance of the common stock offered by this prospectus supplement will be passed upon for us by Cooley LLP, San Diego, California. Cantor
Fitzgerald&nbsp;
&amp; Co. is being represented in connection with this offering by Goodwin Procter LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_9"></A>EXPERTS
 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements incorporated in this prospectus supplement by reference from our Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and the effectiveness of our internal control over financial reporting have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their
reports, which are incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect to the shares of
common stock we are offering under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement.
For further information with respect to us and the common stock we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. We file
annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically
with the SEC, including us. The SEC&#146;s Internet site can be found at www.sec.gov. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom742534_11"></A>INCORPORATION OF
CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information from other documents that we file with it,
which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered part of this prospectus supplement and the accompanying prospectus. Later information filed
with the SEC will update and supersede this information. The SEC&#146;s Internet site can be found at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We incorporate by reference the
documents listed below and any future filings made with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus supplement until the termination of the offering of the shares covered by this prospectus
supplement (other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items and other portions of documents that
are furnished, but not filed, pursuant to applicable rules promulgated by the SEC): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000156459019004263/mnkd-10k_20181231.htm">Form&nbsp;10-K
</A> for the year ended December&nbsp;31, 2018, filed with the SEC on February&nbsp;26, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form&nbsp;10-K for the year
ended December&nbsp;31, 2018 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000114036119005883/bp18389x2_def14a.htm">Schedule&nbsp;14A</A> for our 2019 Annual Meeting of Stockholders, filed with the SEC
on March&nbsp;28, 2019; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000156459019016216/mnkd-10q_20190331.htm">Form&nbsp;10-Q
</A> for the quarter ended March&nbsp;31, 2019, filed with the SEC on May&nbsp;7, 2019; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000095012904005102/v00466e8va12g.htm">Form&nbsp;8-A
</A>, filed with the SEC on July&nbsp;23, 2004, including all amendments and reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any
or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. You should direct any requests for
documents by writing us at 30930 Russell Ranch Road, Suite 300, Westlake Village, California 91362, Attn: Corporate Secretary, or by telephoning us at (818) <FONT STYLE="white-space:nowrap">661-5000.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or
superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g742534g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell up to $500,000,000 of any combination of shares of our common stock, shares of our preferred stock, various series of debt securities and warrants to purchase any of such securities in one or more offerings as described
in this prospectus. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exchange or exercise of any securities registered hereunder, including any applicable antidilution provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides a general description of the securities we may offer. Each time we offer securities, we will provide specific terms
of the securities offered in a supplement to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may
also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before
you invest in any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of any securities unless
accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the symbol &#147;MNKD.&#148; On
March&nbsp;28, 2019, the last reported sales price of our common stock was $1.93 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing on the Nasdaq Global Market or any securities market
or other exchange of the securities, if any, covered by the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will sell these securities directly to investors,
through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#147;Plan of Distribution&#148; in
this prospectus. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts or
over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;<A HREF="#toc742534_3">Risk Factors</A>&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this
prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF
THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is April 5, 2019. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc742534_15">DISCLOSURE OF COMMISSION&#146;S POSITION ON INDEMNIFICATION FOR SECURITIES
 ACT LIABILITY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities
and Exchange Commission, or SEC, utilizing a &#147;shelf&#148; registration process. Under this prospectus, we may sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of
$500,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we sell securities under this prospectus, we will provide a prospectus supplement that will contain specific
information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing
prospectus that we may authorize to be provided to you may also add, update or change information contained in this prospectus or in any documents that we have incorporated by reference into this prospectus. You should read this prospectus, any
applicable prospectus supplement and any related free writing prospectus, together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148; before investing
in any of the securities offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A
PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any agent, underwriter or dealer has authorized any person to give any information or to make
any representation other than those contained or incorporated by reference in this prospectus, any applicable prospectus supplement or any related free writing prospectus prepared by or on behalf of us or to which we have referred you. This
prospectus, any applicable supplement to this prospectus or any related free writing prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor
do this prospectus, any applicable supplement to this prospectus or any related free writing prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make
such offer or solicitation in such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not assume that the information contained in this prospectus, any applicable
prospectus supplement or any related free writing prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the
date of the document incorporated by reference, even though this prospectus, any applicable prospectus supplement or any related free writing prospectus is delivered, or securities are sold, on a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information from this prospectus and does not contain all of the information that you need to consider in
making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#147;Risk
Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the
information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, references in this prospectus to the &#147;Company,&#148; &#147;MannKind,&#148; &#147;we,&#148;
&#147;us&#148; and &#147;our&#148; refer to MannKind Corporation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Company Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases
such as diabetes and pulmonary arterial hypertension. Our only approved product, Afrezza (insulin human) Inhalation Powder, is a rapid-acting inhaled insulin that was approved by the U.S. Food and Drug Administration, or FDA, in June&nbsp;2014.
Afrezza became available by prescription in U.S. retail pharmacies in February 2015.&nbsp;According to the Centers for Disease Control and Prevention, 30.3&nbsp;million people in the United States had diabetes in 2015. Globally, the International
Diabetes Federation has estimated that approximately 425.0&nbsp;million people had diabetes in 2017 and approximately 629.0&nbsp;million people will have diabetes by 2045. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Afrezza </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza is a rapid-acting
inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly
upon inhalation to the lung and delivers insulin quickly to the bloodstream. The first measurable effects of Afrezza occur approximately 12 minutes after administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From August 2014 until April 2016, Sanofi-Aventis U.S. LLC, or Sanofi, was responsible for commercial, regulatory and development activities
associated with Afrezza pursuant to a license and collaboration agreement between us and Sanofi, or the Sanofi License Agreement.&nbsp;The Sanofi License Agreement terminated effective April 2016 and, after a transition period during which Sanofi
continued to fulfill orders for Afrezza, we assumed responsibility for worldwide development and commercialization of Afrezza in July 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, we promote Afrezza to endocrinologists and certain high-prescribing primary care physicians through our specialty sales
force.&nbsp;To support our sales efforts, we have implemented several patient and physician support programs, including a <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance and product savings program, direct purchase and our MannKind Cares
program that supports providers and patients who have questions about insurance coverage, prescription cost and product use. We have also entered into a number of rebate or other agreements with various payors and pharmacy benefit managers that are
intended to facilitate more favorable insurance coverage for Afrezza. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may seek to supplement our sales force through a <FONT
STYLE="white-space:nowrap">co-promotion</FONT> arrangement with a third party that has an underutilized primary care sales force, that can be used to promote Afrezza to greater number of </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
primary care physicians in the United States. Internationally, our strategy is to establish regional partnerships in foreign jurisdictions where there are commercial opportunities, subject to
receipt of the necessary foreign regulatory approvals. In May 2017 we entered into a supply and distribution agreement with Biomm S.A. to pursue regulatory approval and commercialization of Afrezza in Brazil. In May 2018, we entered into a similar
agreement with Cipla Ltd. for the regulatory approval and commercialization of Afrezza in India. Our partners have not yet commenced commercialization in their respective territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to conduct clinical studies of Afrezza, including an open-label pharmacokinetics (PK) and multiple-dose safety and tolerability
dose-titration trial of Afrezza in pediatric patients with type 1 diabetes. The first cohort (patients aged <FONT STYLE="white-space:nowrap">13-17)</FONT> in this study was completed in September 2018. Patients in the second cohort (ages <FONT
STYLE="white-space:nowrap">8-12)</FONT> are currently being recruited and dosed. During the past year, we also supported a collaborative clinical trial with investigators at the Barbara Davis Center for Diabetes, University of Colorado Denver that
examined the effect of Afrezza on post-prandial glucose excursions and glucose <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-in-range</FONT></FONT> using continuous glucose monitors. We have additional collaborative clinical
studies that are underway at this time.&nbsp;As part of the approval of Afrezza, the FDA required us to conduct&nbsp;a five-year, randomized, controlled trial in <FONT STYLE="white-space:nowrap">8,000-10,000</FONT> patients with type 2 diabetes to
assess the potential serious risk of pulmonary malignancy with Afrezza use. We have not yet agreed with the FDA on the final study design for this long-term study. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Technosphere Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe there
are additional opportunities for our proprietary Technosphere and inhaler technologies for the delivery of active pharmaceutical ingredients, or API. We believe that our proprietary Technosphere formulation technology represents a versatile drug
delivery platform that may allow the oral inhalation of a wide range of API. We have successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules.
Technosphere powders are based on our proprietary excipient, fumaryl diketopiperazine, which is a <FONT STYLE="white-space:nowrap">pH-sensitive</FONT> organic molecule that self-assembles into small particles under acidic conditions. Certain drugs,
such as insulin or treprostinil, can be loaded onto these particles by combining a solution of the drug with a solution or suspension of Technosphere material, which is then dried to powder form. The resulting powder has a consistent and narrow
range of particle sizes with good aerodynamic properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve quickly when the particles contact the moist lung surface with its neutral pH, releasing the drug molecules to
diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
also created an innovative line of breath-powered, dry powder inhalers. Our inhalers are easy to use, cost-effective and can be produced in both a reusable (chronic treatment) and a <FONT STYLE="white-space:nowrap">single-use</FONT> (acute
treatment) format. Both the reusable and single use inhaler formats use the same internal <FONT STYLE="white-space:nowrap">air-flow</FONT> design. Being breath-powered, our inhalers require only the patient&#146;s inhalation effort to deliver the
powder. To administer the inhalation powder, a patient loads a cartridge into our inhaler and inhales through the mouthpiece. Upon inhalation, the dry powder is lifted out of the cartridge and broken (or
<FONT STYLE="white-space:nowrap">de-agglomerated)</FONT> into small particles. The inhalers are engineered to produce an aggressive airstream to <FONT STYLE="white-space:nowrap">de-agglomerate</FONT> the powder while keeping the powder moving
slowly. This slow-moving powder effectively navigates the patient&#146;s airways for delivery into the lung with minimal deposition at the back of the throat. Our inhalers show very little change in&nbsp;performance (i.e., efficient cartridge
emptying) over a wide range of inhalation efforts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We advanced an inhaled formulation of treprostinil, or TreT, into clinical
development, completing a Phase 1 dose-escalation study in June 2018. In September 2018, we announced a license and collaboration agreement with United Therapeutics Corporation, or UT, pursuant to which UT became responsible for global development,
regulatory and commercial activities with respect to TreT, or the UT License Agreement. We will manufacture clinical supplies and initial commercial supplies of TreT, whereas long-term commercial supplies may be manufactured by UT. In September
2018, we also signed a research agreement with UT, or the UT Research </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, pursuant to which we will evaluate the feasibility of preparing a dry powder formulation of an additional API for the treatment of pulmonary hypertension. In addition to our activities
under the UT License Agreement and the UT Research Agreement, we intend to advance additional <FONT STYLE="white-space:nowrap">dry-powder</FONT> candidates into formulation feasibility and preclinical studies during the next <FONT
STYLE="white-space:nowrap">12-18</FONT> months. Our internal product development efforts are supplemented by a collaboration and license agreement with Receptor Life Sciences, or Receptor, which we entered into in January 2016, pursuant to which
Receptor is responsible for the development, manufacture and commercialization of inhaled formulations of certain cannabinoid compounds utilizing our technology. To date, Receptor has conducted formulation studies with a range of different API and
has informed us of their plans to commence preclinical development of the most promising powder candidate(s) during 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To aid in the
development of our oral inhalation products, we have created a number of innovative tools such as a novel inhalation profiling apparatus that uses miniature sensors to assess the drug delivery process at the level of an individual inhaler. This
apparatus provides real-time data regarding patient usage and delivery system performance that is transmitted to a user interface, such as a smartphone application. We are currently evaluating the desirability of developing this apparatus further
for use as a training tool in physician offices or as a connected care device that will allow patients to integrate dosing information with other health data, such as blood glucose levels from a self-managed glucose meter or a continuous glucose
monitor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware on February&nbsp;14, 1991. Our principal executive offices are located at 30930 Russell Ranch
Road, Suite 300, Westlake Village, California 91362, and our telephone number at that&nbsp;address is <FONT STYLE="white-space:nowrap">(818)&nbsp;661-5000.</FONT> Our website address is www.mannkindcorp.com. Information contained on or accessible
through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Afrezza <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Technosphere <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>
are our trademarks in the United States. We have also applied for or have registered company trademarks in other jurisdictions. This prospectus also contains references to our trademarks and to trademarks belonging to other entities. Solely for
convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not
intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a
relationship with, or endorsement or sponsorship of us by, any other companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Securities We May Offer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, shares of our preferred stock, various series of debt securities and warrants to purchase any of such
securities, up to a total aggregate offering price of $500,000,000 from time to time in one or more offerings under this prospectus, together with any applicable prospectus supplement and any related free writing prospectus, at prices and on terms
to be determined by market conditions at the time of the relevant offering. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will
provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">important U.S. federal income tax considerations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change
information contained in this prospectus or in documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the
effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale
of securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors or through
underwriters, dealers or agents. We, and our underwriters or agents, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through underwriters or agents, we will include in the
applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of those underwriters or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable fees, discounts and commissions to be paid to them; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">details regarding over-allotment options, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated net proceeds to us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Common Stock</I></B><I>.</I> We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one
vote per share for the election of directors and on all other matters that require stockholder approval. Subject to any preferential rights of any then outstanding preferred stock, in the event of our liquidation, dissolution or winding up, holders
of our common stock are entitled to share ratably in the assets remaining after payment of liabilities and the liquidation preferences of any then outstanding preferred stock. Our common stock does not carry any preemptive rights enabling a holder
to subscribe for, or receive shares of, any class of our common stock or any other securities convertible into shares of any class of our common stock, or any redemption rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock</I></B><I>. </I>We may issue shares of our preferred stock from time to time, in one or more series. Under our amended
and restated certificate of incorporation, as amended, our board of directors has the authority, without further action by stockholders, to designate up to 10,000,000 shares of preferred stock in one or more series and to fix the rights,
preferences, privileges, qualifications and restrictions granted to or imposed upon the preferred stock, including dividend rights, conversion rights, voting rights, rights and terms of redemption, liquidation preference and sinking fund terms, any
or all of which may be greater than the rights of the common stock. To date, none of the 10,000,000 authorized shares of preferred stock have been designated by our board of directors. Convertible preferred stock will be convertible into our common
stock or exchangeable for our other securities. Conversion may be mandatory or at the option of the holders of our preferred stock and would be at prescribed conversion rates. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the rights, preferences, privileges, qualifications and restrictions of the
preferred stock of each series that we sell under this prospectus and applicable prospectus supplements in the certificate of designation relating to that series. We will incorporate by reference into the registration statement of which this
prospectus is a part the form of any certificate of designation that describes the terms of the series of preferred stock we are offering before the issuance of the related series of preferred stock. We urge you, however, to read the applicable
prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the
applicable series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Debt Securities</I></B><I>. </I>We may issue debt securities from time to time, in one or
more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and
junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into our common stock or preferred stock. Conversion may
be mandatory or at the holder&#146;s option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under one or
more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities. We urge you, however, to
read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete indentures that contain the terms of the debt
securities. A form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be
filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B><I>. </I>We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more
series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from these securities. In this prospectus, we have summarized certain general features
of the warrants. We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as the complete
warrant agreements and warrant certificates that contain the terms of the warrants. Forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants being offered have been filed as exhibits to the registration
statement of which this prospectus is a part, and supplemental warrant agreements and forms of warrant certificates will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from
reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue. Warrants may be
issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being
offered. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described under the
heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2018, as updated by our annual, quarterly and other reports and documents that are incorporated by reference into this prospectus and the applicable prospectus supplement, before deciding whether to purchase any of the securities
being registered pursuant to the registration statement of which this prospectus is a part. Each of the risk factors could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an
investment in our securities, and the occurrence of any of these risks might cause you to lose all or part of your investment. Additional risks not presently known to us or that we currently believe are immaterial may also significantly impair our
business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this prospectus, the applicable prospectus supplement and in the documents incorporated by reference herein and
therein that are not strictly historical in nature are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and within the meaning of Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are subject to the &#147;safe harbor&#148; created by Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and may include, but are
not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully market, commercialize and achieve market acceptance for Afrezza or any other product
candidates or therapies that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to manufacture sufficient quantities of Afrezza and obtain insulin supply as needed;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our Technosphere drug delivery platform; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates for future performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding anticipated operating losses and financial results and our needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress or success of our research, development and clinical programs, including the application for and
receipt of regulatory clearances and approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to protect our intellectual property and operate our business without infringing upon the
intellectual property rights of others </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">scientific studies and the conclusions we draw from them; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of proceeds from the sale of securities under this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;anticipates,&#148; &#147;believes,&#148; &#147;could,&#148;
&#147;estimates,&#148; &#147;expects,&#148; &#147;goal,&#148; &#147;intends,&#148; &#147;may,&#148; &#147;plans,&#148; &#147;potential,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would,&#148; the
negative of these words and words or similar expressions intended to identify forward-looking statements. These statements reflect our views as of the date on which they were made with respect to future events and are based on assumptions and
subject to risks and uncertainties. The underlying information and expectations are likely to change over time. In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given these uncertainties, you should not place undue reliance on these forward-looking statements as actual events or results may differ
materially from those projected in the forward-looking statements due to various factors, including, but not limited to, those set forth under the heading &#147;Risk Factors&#148; in any applicable prospectus supplement, the documents incorporated
by reference therein or any free writing prospectus that we authorized. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Our actual future results may
be materially different from what we expect. We qualify all of the forward-looking statements contained in this prospectus, in the documents incorporated by reference herein and in any prospectus supplement by these cautionary statements. Unless
required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing
out as expressed or implied in such forward-looking statements. Before deciding to purchase our securities, you should carefully consider the risk factors discussed herein or incorporated by reference, in addition to the other information set forth
in this prospectus, any accompanying prospectus supplement or free writing prospectus and in the documents incorporated by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any prospectus supplement or in any related free writing prospectus that we may authorize to be provided to you, we
currently intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses, sales and marketing expenses,
general and administrative expenses, and other expenses associated with the commercialization of Afrezza, any other product candidate we develop and our Technosphere drug delivery platform. We may also use a portion of the net proceeds to <FONT
STYLE="white-space:nowrap">in-license,</FONT> invest in or acquire businesses, assets or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions. As of
the date of this prospectus, we cannot specify with certainty all of the particular uses of the proceeds from the sale of securities under this prospectus. Accordingly, we will retain broad discretion over the use of such proceeds. Pending the use
of the net proceeds from the sale of securities under this prospectus as described above, we intend to invest the net proceeds in investment-grade, interest-bearing instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock
consists of 280,000,000 shares of common stock, $0.01 par value, and 10,000,000 shares of preferred stock, $0.01 par value. All of our authorized preferred stock is undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary description of our capital stock is based on the provisions of our certificate of incorporation and bylaws and the
applicable provisions of the Delaware General Corporation Law, or DGCL. This information is qualified entirely by reference to the applicable provisions of our certificate of incorporation, bylaws and the Delaware General Corporation Law. For
information on how to obtain copies of our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus is a part, see &#147;Where You Can Find More Information&#148; and &#147;Incorporation of
Certain Information Reference.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights</I>. Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of our
stockholders, including the election of our directors. Under our certificate of incorporation and bylaws, our stockholders will not have cumulative voting rights. Accordingly, the holders of a majority of our outstanding shares of common stock
entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. In all other matters, an action by our common stockholders requires the affirmative vote of the holders of a majority of
our outstanding shares of common stock entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to preferences that may be applicable to any
outstanding shares of our preferred stock, holders of our common stock are entitled to receive ratably any dividends our board of directors declares out of funds legally available for that purpose. Any dividends on our common stock will be <FONT
STYLE="white-space:nowrap">non-cumulative.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation, Dissolution or Winding Up</I>. If we liquidate, dissolve or wind up,
the holders of our common stock are entitled to share ratably in all assets legally available for distribution to our stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted
to the holders of any outstanding shares of our preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights and Preferences</I>. Our common stock has no preemptive,
conversion or subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of any outstanding shares of our preferred stock, which we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such
stockholder action is required by applicable law or Nasdaq rules), to designate and issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to
fix the designations, voting powers, preferences and rights of the shares of each wholly unissued series, and any qualifications, limitations or restrictions thereof, and to increase or decrease the number of shares of any such series, but not below
the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of the
preferred stock of each series, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a
part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
terms of the series of preferred stock we are offering before the issuance of that series of preferred stock. This description will include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate per share, dividend period, payment date or dates and method of calculation for dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of dividends and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock or other securities of ours, including
warrants, and, if applicable, the conversion price, or how it will be calculated, and under what circumstances and the mechanism by which it may be adjusted, and the conversion period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities or other securities of ours, and, if
applicable, the exchange price, or how it will be calculated, and under what circumstances it may be adjusted, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuances of any class or series of preferred stock ranking senior to or on parity with the
series of preferred stock being issued as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, rights, preferences, privileges, qualifications or limitations of, or restrictions on
the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue shares of preferred stock under this prospectus, the shares will be fully-paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides that the holders of preferred stock will have the right to vote
separately as a class (or, in some cases, as a series) on an amendment to our certificate of incorporation if the amendment would change the par value or, unless the certificate of incorporation provided otherwise, the number of authorized shares of
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
class or change the powers, preferences or special rights of the class or series so as to adversely affect the class or series, as the case may be. This right is in addition to any voting rights
that may be provided for in the applicable certificate of designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may authorize the issuance of preferred
stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our
company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation, Our Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
subject to Section&nbsp;203 of the DGCL, which generally prohibits a public Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years after the date of the
transaction in which the person became an interested stockholder, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prior to the date of the transaction, the board of directors of the corporation approved either the business
combination or the transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interested stockholder owned at least 85% of the voting stock of the corporation outstanding upon
consummation of the transaction, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are directors and also officers and (2)&nbsp;shares owned by employee stock plans in which employee
participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or subsequent to the consummation of the transaction, the business combination is approved by the board and
authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 of the DGCL defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets
of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 of the DGCL defines an
interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of our amended and restated certificate of incorporation, as amended, and amended and restated bylaws, may delay or discourage
transactions involving an actual or potential change in our control or change in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best
interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation, as amended, and amended and restated bylaws: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences
and privileges as they may designate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that, subject to the rights of the holders of any outstanding series of preferred stock, all vacancies,
including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our board of directors may fix the number of directors by resolution; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special
meeting of stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates
for election as directors at a meeting of stockholders must provide timely notice in writing and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common
stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that special meetings of our stockholders may be called only by the Chairman of our board of directors,
by our Chief Executive Officer, by our board of directors upon a resolution adopted by a majority of the total number of authorized directors or, under certain limited circumstances, by the holders of at least 5% of our outstanding voting stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
2335 Alaska Avenue, El Segundo, California 90245. The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement for that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing on the Nasdaq Global Market </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the Nasdaq Global Market under the symbol &#147;MNKD.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any, and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice
of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us,
the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities-Consolidation, Merger or
Sale;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities-General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights
of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the
principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the
applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be
deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in
global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the
applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement,
holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of
the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any
registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the
applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the
designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements and free writing
prospectuses, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series.
Warrants may be issued independently or together with common stock, preferred stock or debt securities offered by any prospectus supplement, and may be attached to or separate from those securities. While the terms we have summarized below will
apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants that we may offer in more detail in the applicable prospectus supplement and any applicable free writing
prospectus. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. However, no prospectus supplement will fundamentally change the terms that are set forth in this prospectus or offer a security
that is not registered and described in this prospectus at the time of its effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements
as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the
form of warrant agreement, if any, including a form of warrant certificate, that describes the terms of the particular series of warrants we are offering. The following summaries of material provisions of the warrants and the warrant agreements are
subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to the particular series of warrants that we may offer under this prospectus. We urge you to read the
applicable prospectus supplements related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete warrant agreements and warrant certificates that contain the
terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will describe in the applicable prospectus supplement the terms relating to a series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price or prices and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at which, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which, and the currency in which, these shares may be purchased upon such exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to force the exercise of the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax consequences of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set
forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants by delivering the
warrant certificate representing the warrants to be exercised together with specified information, and paying the required amount to the warrant agent in immediately available funds, as provided in the applicable prospectus supplement. We will set
forth on the reverse side of the warrant certificate and in the applicable prospectus supplement the information that the holder of the warrant will be required to deliver to the warrant agent in connection with the exercise of the warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of the required payment and the warrant certificate properly completed and duly executed at the corporate trust office of the
warrant agent or any other office indicated in the applicable prospectus supplement, we will issue and deliver the securities purchasable upon such exercise. If fewer than all of the warrants represented by the warrant certificate are exercised,
then we will issue a new warrant certificate for the remaining amount of warrants. If we so indicate in the applicable prospectus supplement, holders of the warrants may surrender securities as all or part of the exercise price for warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide
otherwise in the applicable prospectus supplement, the warrants and warrant agreements, and any claim, controversy or dispute arising under or related to the warrants or warrant agreements, will be governed by and construed in accordance with the
laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable
warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any
other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee or depositary maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal
holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names as &#147;indirect holders&#148; of those securities. As we discuss below, indirect
holders are not legal holders and investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may
be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These
participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Global securities will be registered in
the name of the depositary or its participants. Consequently, for global securities, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes
along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their
customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a global security will not own
securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As
long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may be terminated in certain situations as described under &#147;-Special Situations When a Global Security Will Be
Terminated,&#148; or issue securities that are not issued in global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be
registered in the name of a bank, broker or other financial institution that the investor chooses, and&nbsp;the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other
financial institutions in whose names the securities are registered as the holders of those securities, and we or any such trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they
receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not
holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee or third party employed by us or a trustee, run only to the legal holders
of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or
has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the legal holder, we have no further
responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval
of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of an indenture, or for other purposes. In such an event, we would seek approval only from the legal
holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented
by one or more global securities or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify
otherwise in the applicable prospectus supplement, the DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global
security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#147;-Special Situations
When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be
permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution
that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued as a global security, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations for Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As an indirect holder, an investor&#146;s rights relating to a global security will be governed by the account rules of the investor&#146;s
financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only as global securities, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in the global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in the global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in the global security, nor will we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in the
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in the global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, a global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own names, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security will terminate when the following special situations occur: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the prospectus supplement. When a global security terminates, the depositary, and neither we nor any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination
of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also sell equity securities covered by this registration statement in an &#147;at the market offering&#148; as defined in Rule 415
under the Securities Act. Such offering may be made into an existing trading market for such securities in transactions at other than a fixed price, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on or through the facilities of the Nasdaq Global Market or any other securities exchange or quotation or trading
service on which such securities may be listed, quoted or traded at the time of sale; and/or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through a market maker other than on the Nasdaq Global Market or such other securities exchanges or
quotation or trading services. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such &#147;at the market offerings&#148;, if any, may be conducted by underwriters
acting as principal or agent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be
provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds we will receive from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement are underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a
material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will
name any agent involved in the offering and sale of securities, and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis
for the period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors
to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these
contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and
underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these
liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than common stock, all securities we offer will be new issues of securities with no established trading market. Any underwriters may
make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids. Overallotment involves
sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. Short covering transactions involve
purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are
purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time. These transactions may be effected on any exchange or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters who are qualified market makers on the Nasdaq Global Market may engage in passive market making transactions in the
securities on the Nasdaq Global Market in accordance with Rule 103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with
applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are
lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the securities at a level above
that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, certain legal matters in connection with the offering and the validity of
the securities offered by this prospectus, and any supplement thereto, will be passed upon by Cooley LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements incorporated in this prospectus by reference from MannKind Corporation&#146;s Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;and</FONT> the effectiveness of our internal control over financial reporting have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their
reports, which are incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth
in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and
schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer
is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities
offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC
maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC, including MannKind. The address of the SEC website is www.sec.gov. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a website at www.mannkindcorp.com. Information contained in or accessible through our website does not constitute a part of this
prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information that we file with it, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed with the SEC
prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We also incorporate by reference into this prospectus the documents listed below and
any future filings made by us with the SEC (other than Current Reports or portions thereof furnished under Item&nbsp;2.02 or Item&nbsp;7.01 <FONT STYLE="white-space:nowrap">of&nbsp;Form&nbsp;8-K&nbsp;and&nbsp;exhibits</FONT> filed on such form that
are related to such items and other portions of documents that are furnished, but not filed, pursuant to applicable rules promulgated by the SEC) that are filed by us with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange
Act (i)&nbsp;after the date of the initial filing of the registration statement of which this prospectus is a part and prior to effectiveness of the registration statement, and (ii)&nbsp;after the effectiveness of the registration statement but
prior to the termination of the offering of the common stock covered by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000156459019004263/mnkd-10k_20181231.htm">Form
 10-K</A> for the fiscal year ended December 31, 2018, filed with the SEC on February 26, 2019 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000114036119005883/bp18389x2_def14a.htm">Schedule
 14A</A>, which was filed on March 28, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock, which is registered under Section 12 of the Exchange Act, in our
registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/899460/000095012904005102/v00466e8va12g.htm">Form 8-A</A>, filed with the SEC on July 23, 2003, including all amendments or reports filed for the purpose of updating such
description </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without
charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such
documents. You should direct any requests for documents by writing us at 30930 Russell Ranch Road, Suite 300, Westlake Village, California 91362, Attn: Corporate Secretary, or by telephoning us at (818)
<FONT STYLE="white-space:nowrap">661-5000.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained herein or in a document incorporated or deemed to be
incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be
incorporated by reference into this document modifies or supersedes the statement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc742534_15"></A>DISCLOSURE OF
COMMISSION&#146;S POSITION ON INDEMNIFICATION FOR </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES ACT LIABILITY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the
Company pursuant to the DGCL, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$50,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g742534g38c99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus
Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:70pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g742534g55u86.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:70pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;7, 2019 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g742534g38c99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g742534g38c99.jpg
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M;OB)Y2_8Z@_9BFD]FR[%'>UY!.Z%J:9ZN$>7U1>X<F:J$B0E3HYB)*DM<P@
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MIJZXVDD9[V&F5C #KW.&JH3TIS$4TIC%144[(S8ST1'@.4;D?EQNB?E5ZO\
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M.ONDY<0>K#P+1;0ZP)B2G!Z*))1D-](ZZ3]ACZU(SMJ*L$P[#PREI"CX](9
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MI)*6T>\CF>D"T<B2]J,4;I"A8\)6N1F7V!L'+>Y<I<A:3KVWOJJ^'97*+.E
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MHUW,26$9G,@"6[]9;C#R_=)^1=RUB=\.NIZ_7;+3RKL%5I()M/$LXI; 2PX
M$EADPQ%4S?3&&WSL(S]T1B=Z(YJ=(WQYI^S0OB%VN_L-<MXU*>TW0\.WE5DD
M5>5)D\RQ2QYA1(!WJ0D7PO&1?(-Z]BJUR]>/[G]'NSG03O93>\/CJU9<=@TZ
M_34B;?\ 3^N:Y,SXT-(2+K95YIDO7:Z(84UK'8@^%RT*4P&X+3;2RX@!,2Y&
M4Q+GIH'(NH<F<;S^.^5+F#63ZR.(=9>VLL$9\@0FJRMG@E2GC8ZWJG] 2&.>
MCY\-R*53(:>J>6^\>[=QMR+!Y"XNIYUG LI!265'513R61RE5K[& >+%8]Z5
M-HWJ8#VL5D&8U4'X%% 19,[>Z[WIV-\H?C![,4SKGOJ.UQ'5G1LIL(JPZLM\
M8YJ>1CMWW:8LE>V*Z]$I%KDE6A24/R#ACS83\<X+-@$DPT@"<19]&M=<U7AW
MF'49^U:T6U-,V$-6R+<P2I=B)K]>")*JFM,KY09;VJT2,:I&E1\<C62!$&V[
M[O5[%M/+W$6VP-6V054*'KQK-\JGG"6E*+8+ \N+:.<%&131&/1Q5(Y!N$K)
M W/ 49'=\ZM=?]Y5KSO=L=UV'4&R(33]HI=X$KFSY6FSP%#G2C6]58$&B;42
M"W"R#Y.8R1PPT*8ZMWZ)?LQGZ[OMMNY;/KDOX;M)UZ+>U,B]AV%>273AGQB6
M49@W77>\\-A%.)K/,+N5[$1/(SK]Y.MQT[6=BB?$9NE_*H[6/1S(%BR+;F@2
M1ULEY$INQH)CQH KG^(O:C"*J^-_3[J]/[V5U_WC(_Q!^FM[ Z@V.;I2)I"0
MI7:XU-GG]>1Y7]@.QX+(IMN;!5!#O?F9 &*RT\:E?Y P83T^=YM"E1L^N!^%
M^_ULE[5#V ]@I 4KY\9MH5G[354GO'!4B2'-\ B&ZM&J>(;W_=:JY^VVM;"7
MXFJ'8QT=J2@#7^,URR!)=5B?^S5K&["34&L=CO.48>CB(OD>QGWG(BT\ZY17
M=/PN]ENQ5 @.F6V>U&A-SS4>509_5439)'#XU=D+"[0Y!N<KM3N8L9,*AK,7
M!W&I3P4?()D!!Y2*+)BP6'IR=[6;C_G_ %'5;.3OU'IFRT$<K+.+<GB"5KY0
MHJ60EC2IM>\P$D0V2($V,0HE$]P3,88CFQX/JH=]X%VO::R-H=UN.MWT@3ZR
M33!E%[F12R5KB)(BPI[ F]/+)'G0I(Q%0K&&"1X1M=(ECH'JSNM8_,CLSM+V
M6ZV7_4@&QM<V@Y^2=KTR9K^O-2M0H@U*I;-^^BW S$Y"U@"-@)?+)#1#E@B9
M=AT(,H<@,>R<F7/'T7@6HTW4MMK+PM5:PQM"V4 =G*4,ZR?86#JWR+)!'D3"
MEE [FJU(IP.:]['->Z\<:T^_RN=K7<=LU2RI!VE7,(XKHIWUD5IH-<R! ;9>
M-L8\B/$&&,;M<URR0G:X8WM>-NQ9V<T/7>SW7[;>@;22X!#[2I<K6,RK3*27
MH.4>0DJOV%@92VT%/UZ?%C)M@5QQMLET!##BTH<4K&J^H;)*T_9Z/9H3$*>F
ML 3/"YW8V0%JJR3%<_HY6-E1GFCN>C55B$5R(JHF;2;=KD7;M9N]:F/40+B
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MZ_;+$/E9V%@"[/9Y9D^'B&POO-!QWD7<M)U/CG7N'].OH^S**QA2+RZBO&2
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M.14OF@:5NNQ[EN/+.WTAZ UC3VD6EI##(RP(:36,K(Z+%(ULE@XM:%(B+)
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1QQC'&,<8QQC'&,<8QQC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g742534g55u86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g742534g55u86.jpg
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M6 NRY3'8^\-O0E(VQ[?AOS423_CN?7BHO!R]YO15> MNV-OWJ1^H5Y%O+O\
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ME1E3)7*U.L6&W/'CDF:61/JC37#%S>G/ Z^JGB9?'3*Q3Y3#8B-PSX^K8MV
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M@JPQI!5B9AL7$48'/(1N.I*TDBJ2JL%)''?7%CBK,Z<TW+]2/D35?P73NLB
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M_B&Q6AM=R<R+X>&1[':X 6W69I6/MW4BP3LFE2LXPI:L96K&%*SC'SYUQ?\
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CJU'X;"S6;5AEHBS);6N6L32EUCGED:(N6:)7,4;+%LG'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
